Total Payments
$218,980
2024 Payments
$19,179
Companies
13
Transactions
138
Medicare Patients
452
Medicare Billing
$55,484
Payment Breakdown by Category
Consulting$166,436 (76.0%)
Research$40,297 (18.4%)
Travel$6,192 (2.8%)
Food & Beverage$6,010 (2.7%)
Education$45.34 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $166,436 | 76 | 76.0% |
| Unspecified | $40,297 | 20 | 18.4% |
| Travel and Lodging | $6,192 | 13 | 2.8% |
| Food and Beverage | $6,010 | 26 | 2.7% |
| Education | $45.34 | 3 | 0.0% |
Payments by Type
General
$178,683
118 transactions
Research
$40,297
20 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $63,887 | 25 | $0 (2024) |
| UCB SA | $43,320 | 18 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $28,793 | 48 | $0 (2024) |
| Octapharma USA, Inc. | $24,625 | 13 | $0 (2020) |
| UCB Biosciences Inc. | $22,540 | 3 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $13,650 | 8 | $0 (2024) |
| Amgen Inc. | $8,474 | 10 | $0 (2021) |
| ARGENX US, INC. | $7,403 | 5 | $0 (2024) |
| Celgene Corporation | $3,115 | 2 | $0 (2018) |
| EMD Serono Research & Development Institute, Inc. | $1,250 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $19,179 | 12 | PFIZER INC. ($8,461) |
| 2023 | $19,681 | 18 | PFIZER INC. ($7,331) |
| 2022 | $34,225 | 17 | UCB SA ($16,808) |
| 2021 | $23,198 | 15 | UCB SA ($7,623) |
| 2020 | $20,110 | 16 | UCB SA ($10,175) |
| 2019 | $58,119 | 29 | PFIZER INC. ($22,652) |
| 2018 | $25,175 | 18 | Octapharma USA, Inc. ($13,125) |
| 2017 | $19,295 | 13 | PFIZER INC. ($11,250) |
All Payment Transactions
138 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | ARGENX US, INC. | — | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| 12/04/2024 | ARGENX US, INC. | — | Consulting Fee | Cash or cash equivalent | $2,152.50 | General |
| 11/27/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $1,938.17 | General |
| 06/21/2024 | UCB SA | Cimzia (Drug) | Consulting Fee | Cash or cash equivalent | $2,490.00 | General |
| Category: Immunology | ||||||
| 05/24/2024 | Janssen Scientific Affairs, LLC | REMICADE (Biological) | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| Category: Immunology | ||||||
| 05/24/2024 | Janssen Scientific Affairs, LLC | REMICADE (Biological) | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| Category: Immunology | ||||||
| 05/24/2024 | Janssen Scientific Affairs, LLC | REMICADE (Biological) | Food and Beverage | Cash or cash equivalent | $300.00 | General |
| Category: Immunology | ||||||
| 05/24/2024 | Janssen Scientific Affairs, LLC | REMICADE (Biological) | Travel and Lodging | Cash or cash equivalent | $300.00 | General |
| Category: Immunology | ||||||
| 03/18/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $3,322.92 | General |
| 02/22/2024 | PFIZER INC. | LITFULO (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: PF07038124 BREPOCITINIB DAZUKIBART PF06763809 DEKAVIL PF06817024 PF06480605 RITLECITINIB ZIMLOVISERTIB PF06826647 PF06835375 MULTI PRODUCT PF07054894 PF06473871 CLINICAL PUBLICATION PROGRAM • Category: IMMUNOLOGY | ||||||
| 01/05/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| 01/03/2024 | ARGENX US, INC. | — | Consulting Fee | Cash or cash equivalent | $2,625.00 | General |
| 11/24/2023 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $2,416.66 | General |
| 10/25/2023 | ARGENX US, INC. | — | Consulting Fee | Cash or cash equivalent | $1,125.00 | General |
| 10/10/2023 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $483.33 | General |
| 09/08/2023 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $33.00 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 08/07/2023 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| 07/26/2023 | EMD Serono Research & Development Institute, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,250.00 | General |
| 07/20/2023 | UCB SA | Cimzia (Drug) | Consulting Fee | Cash or cash equivalent | $1,660.00 | General |
| Category: Immunology | ||||||
| 07/06/2023 | ARGENX US, INC. | — | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| 06/23/2023 | UCB SA | — | Consulting Fee | Cash or cash equivalent | $830.00 | General |
| 06/02/2023 | PFIZER INC. | — | — | In-kind items and services | $940.00 | Research |
| Study: BREPOCITINIB CLINICAL PUBLICATION PROGRAM | ||||||
| 05/29/2023 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $1,812.50 | General |
| 05/19/2023 | PFIZER INC. | — | — | In-kind items and services | $330.00 | Research |
| Study: BREPOCITINIB CLINICAL PUBLICATION PROGRAM | ||||||
| 05/11/2023 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $14.95 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| GAM10-08 | Octapharma USA, Inc. | $24,625 | 13 |
| A PHASE 2A DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF PF06823859 IN ADULT SUBJECTS WITH DERMATOMYOSITIS | PFIZER INC. | $9,602 | 1 |
| PF07038124 BREPOCITINIB DAZUKIBART PF06763809 DEKAVIL PF06817024 PF06480605 RITLECITINIB ZIMLOVISERTIB PF06826647 PF06835375 MULTI PRODUCT PF07054894 PF06473871 CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| BREPOCITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,270 | 2 |
| ZIMLOVISERTIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,270 | 2 |
| RITLECITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 112 | 188 | $43,195 | $16,132 |
| 2022 | 4 | 116 | 169 | $37,821 | $13,885 |
| 2021 | 4 | 122 | 164 | $44,853 | $15,571 |
| 2020 | 4 | 102 | 137 | $47,767 | $9,896 |
Total Patients
452
Total Services
658
Medicare Billing
$55,484
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 51 | 94 | $21,248 | $7,623 | 35.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 19 | 27 | $6,167 | $3,421 | 55.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 27 | 52 | $11,970 | $2,768 | 23.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 15 | 15 | $3,810 | $2,321 | 60.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 55 | 86 | $22,336 | $6,945 | 31.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 19 | 23 | $5,168 | $2,833 | 54.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 27 | 45 | $6,987 | $2,371 | 33.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 15 | 15 | $3,330 | $1,735 | 52.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 63 | 93 | $27,816 | $7,967 | 28.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 30 | 39 | $11,334 | $4,898 | 43.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 13 | 13 | $2,966 | $1,638 | 55.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 16 | 19 | $2,737 | $1,070 | 39.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 44 | 67 | $24,095 | $4,693 | 19.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 32 | 44 | $16,403 | $3,837 | 23.4% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 14 | 14 | $4,367 | $897.53 | 20.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 12 | 12 | $2,902 | $468.49 | 16.1% |
About Dr. David Fiorentino, MD
Dr. David Fiorentino, MD is a Dermatology healthcare provider based in Stanford, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/24/2007. The National Provider Identifier (NPI) number assigned to this provider is 1740335025.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Fiorentino, MD has received a total of $218,980 in payments from pharmaceutical and medical device companies, with $19,179 received in 2024. These payments were reported across 138 transactions from 13 companies. The most common payment nature is "Consulting Fee" ($166,436).
As a Medicare-enrolled provider, Fiorentino has provided services to 452 Medicare beneficiaries, totaling 658 services with total Medicare billing of $55,484. Data is available for 4 years (2020–2023), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Stanford, CA
- Active Since 01/24/2007
- Last Updated 04/16/2024
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1740335025
Products in Payments
- REMICADE (Biological) $27,000
- OCTAGAM (Biological) $18,125
- Cimzia (Drug) $9,100
- OCTAGAM IMMUNE GLOBULIN (HUMAN) (Biological) $6,500
- LITFULO (Drug) $3,200
- Otezla (Drug) $3,115
- STELARA (Biological) $1,793
- BRUKINSA (Drug) $600.00
- XELJANZ (Drug) $33.00
- CIBINQO (Drug) $30.54
- Skyrizi (Biological) $14.80
- Enbrel (Biological) $9.30
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Stanford
Matthew Lewis, Md, MD
Dermatology — Payments: $303,775
Dermatology $303,775
Justin Ko, Md, MD
Dermatology — Payments: $243,220
Dermatology $243,220
Zakia Rahman, Md, MD
Dermatology — Payments: $171,847
Dermatology $171,847
Anne Lynn Chang, Md, MD
Dermatology — Payments: $148,354
Dermatology $148,354
Youn-Hee Kim, Md, MD
Dermatology — Payments: $87,849
Dermatology $87,849
Matt Marinkovich, Md, MD
Dermatology — Payments: $63,624
Dermatology $63,624